SABCS2014: CALGB 40603/150709 (Alliance): William M. Sikov

SABCS2014: CALGB 40603/150709 (Alliance): William M. Sikov

William M. Sikov: CALGB 40603Подробнее

William M. Sikov: CALGB 40603

William M SikovПодробнее

William M Sikov

Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to TreatmentПодробнее

Dr. William Sikov on Triple-Negative Breast Cancer Patients Not Responding to Treatment

Survival outcomes from the CALGB 40603 study in triple-negative breast cancerПодробнее

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

SABCS 2014: Rita Nanda, Chicago (pembrolizumab)Подробнее

SABCS 2014: Rita Nanda, Chicago (pembrolizumab)

Dr. Arteaga Discusses the CALGB 40603 TrialПодробнее

Dr. Arteaga Discusses the CALGB 40603 Trial

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC SubtypeПодробнее

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCR

Hope S. Rugo: CALGB 40502/NCCTG N063HПодробнее

Hope S. Rugo: CALGB 40502/NCCTG N063H